Curated news and analysis on clinical trials, drug approvals, and medical research.
University of Alberta researchers have identified the protease GlpG as a new drug target for antibiotic-resistant E. coli, which causes hundreds of thousands of UTI deaths annually. Inhibiting GlpG prevented bacterial adhesion and biofilm formation in laboratory studies. The discovery addresses a global health emergency as antimicrobial resistance projections show it could cause cancer-level deaths by 2050.
Novartis has announced three separate partnership deals worth over $5 billion combined with Antares Therapeutics, Orionis Biosciences, and Unnatural Products. The agreements target undruggable cancers, molecular glue drugs, and cardiovascular therapies respectively using each partner's proprietary platforms.
HHS launches broad initiative to boost US clinical trials amid global competition with China. FDA introduces real-time clinical trial monitoring and expedited programs. NIH Long COVID trials set to begin enrolling participants in summer 2026.
Multiple new studies highlight key factors affecting children's health and development. Research shows maternal cardiovascular health during pregnancy significantly impacts child developmental delays, with poor heart health increasing risk by 62%. A separate study found family finances and neighborhood opportunities account for about 16% of variability in children's brain function, while parental concern about illness proved highly accurate for detecting serious conditions in children.
